LFG
MGX icon

Larson Financial Group’s Metagenomi Therapeutics MGX Stock Holding History

Larson Financial Group’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$67 Hold
50
– – ﹤0.01% 3539
2025
Q4 		$81 Hold
50
– – ﹤0.01% 3353
2025
Q3 		$119 Sell
50
-76
-60% -$154 ﹤0.01% 3310
2025
Q2 		$186 Hold
126
– – ﹤0.01% 3072
2025
Q1 		$171 Buy
126
+76
+152% +$181 ﹤0.01% 2824
2024
Q4 		$181 Hold
50
– – ﹤0.01% 2469
2024
Q3 		$109 Hold
50
– – ﹤0.01% 2518
2024
Q2 		$204 Hold
50
– – ﹤0.01% 2064
2024
Q1 		$528 Buy
+50
New +$575 ﹤0.01% 1552

Other funds holding MGX

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $122M AUM 67.29% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Larson Financial Group's MGX Position: Q1 2026 in Review

Larson Financial Group held its Metagenomi Therapeutics (MGX) position steady in Q1 2026 at 50 shares worth $67. The position accounts for ﹤0.01% of the portfolio, ranked #3539.

Larson Financial Group first reported a position in MGX in Q1 2024 and has held it in 9 quarters since. The position peaked at $528 in Q1 2024. 48 funds tracked by Wall St. Rank hold MGX as of Q1 2026.

  • Larson Financial Group held 50 shares of Metagenomi Therapeutics worth $67 as of Q1 2026.
  • Larson Financial Group left its Metagenomi Therapeutics share count unchanged in Q1 2026.
  • Metagenomi Therapeutics made up ﹤0.01% of Larson Financial Group's portfolio in Q1 2026, its #3539 holding.
  • Larson Financial Group first reported a position in Metagenomi Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • Larson Financial Group's Metagenomi Therapeutics position peaked at $528 in Q1 2024.
  • 48 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q1 2026.

Based on Larson Financial Group's 13F filing for Q1 2026, filed 15 May 2026.